The C609T (Pro187Ser) Null Polymorphism of the NQO1 Gene Contributes Significantly to Breast Cancer Susceptibility in North Indian Populations: a Case Control Study |
Yadav, Prasant
(Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals)
Mir, Rashid (Prince Fahad Bin Sultan Scientific Chair, Faculty of Applied Medical Sciences, Tabuk University) Nandi, Kajal (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) Javid, Jamsheed (Prince Fahad Bin Sultan Scientific Chair, Faculty of Applied Medical Sciences, Tabuk University) Masroor, Mirza (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) Ahmad, Imtiyaz (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) Zuberi, Mariyam (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) Kaza, RCM (Dept. of Surgery, Maulana Azad Medical College and Associated Hospitals) Jain, SK (Dept. of Surgery, Maulana Azad Medical College and Associated Hospitals) Khurana, Nita (Dept. of Pathology, Maulana Azad Medical College and Associated Hospitals) Ray, Prakash Chandra (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) Saxena, Alpana (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) |
1 | Ambrosone CB (2000). Oxidants and antioxidants in breast cancer. Antioxid Redox Signal, 2, 903-17. DOI |
2 | di Martino E1, Hardie LJ, Wild CP, et al (2007). "The NAD(P) H:quinone oxidoreductase I C609T polymorphism modifies the risk of barrett esophagus and esophageal adenocarcinoma." Genetics Med, 9, 341-7. DOI |
3 | Fagerholm R, Hofstetter B, Tommiska J, et al (2008). NAD(P) H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet, 40, 844-53. DOI |
4 | Hamajima N, Matsuo K, et al (2002). NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol, 7, 103-8. |
5 | Jana Sarmanova, Simona Su sova, Ivan Gut, et al (2004). Breast cancer: role of polymorphisms in biotransformation enzymes. Eur J Human Genetics, 12, 848-54. DOI |
6 | Jay H. Fowke, Xiao-Ou Shu, Qi Dai, et al (2004). Genetic Polymorphisms Modification by NAD(P)H:Quinone oxoreductase (NQO1) oral contraceptive use and breast cancer risk. cancer epidemiol biomarkers prev, 13, 1308-15. |
7 | Kuehl BL, Paterson JW, Peacock JW, et al (1995). Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer, 72, 555-561. DOI |
8 | Lewis SJ, NM Cherry (2001). Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer, 34, 177-183. DOI |
9 | Menzel HJ, J Sarmanova, et al (2004). Association of NQO1 polymorphism with spontaneous breast cancer in two independentpopulations. Br J Cancer, 90, 1989-94. DOI |
10 | Moran JL, Siegel D, Ross D (1999). A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc Natl Acad Sci USA, 96, 8150-5. DOI |
11 | Menzel HJ, J Sarmanova (2004). Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer, 90, 1989-94. DOI |
12 | Nowell SA, Ahn J, Ambrosone CB, et al (2004). Gene-nutrient interactions in cancer etiology. Nutr Rev, 62, 427-38. DOI |
13 | Niwa Y, K Hirose (2005). Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects. Gynecologic Oncol 96, 423-9. DOI |
14 | Nebert DW, Roe AL, Vandale SE, Bingham E, Oakley GG (2002) NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a huge review. Genet Med, 4, 62-70 DOI |
15 | Rauth AM, Goldberg Z, Misra V (1997) DT-diaphorase: possible roles in cancer. chemotherapy and carcinogenesis. Oncol Res, 9, 339-49. |
16 | Ross D, Traver RD, Siegel D, et al (1996). A polymorphism in NAD(P)H: quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. Br J Cancer, 74, 995-6. DOI |
17 | Siegel D, McGuinness SM, Winski SL, Ross D (1999). Genotypephenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 9, 113-21. DOI |
18 | Siegel D, Anwar A,Winski SL, Kepa JK, Dowd KL (2001). Rapid polyubiquination and proteasomal degradation of a mutant form of NAD(P)H: quinone oxidoreductase 1. Mol Pharmacol, 59, 263-8. DOI |
19 | Singh V, Upadhyay G, Rastogi N, Singh K, Singh MP (2011) Polymorphism of xenobiotic-metabolizing genes and breast cancer susceptibility in North Indian women. Genet Test Mol Biomarkers, 15, 343-349. DOI |
20 | Traver RD, Siegel D, Beall HD, et al (1997) Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer, 75, 69-75. DOI |
21 | Wyllie S, Liehr JG (1997) Release of iron from ferritin storage by redox cyclingof stilbene and steroid estrogen metabolites: a mechanism of induction of free radical damage by estrogen. Arch Biochem Biophys, 346, 180-6. DOI |